A Chinese delegation led by Vice Premier Liu He could be sent before month's end to iron out phase one, a source tells CNBC's Kayla Tausche.Marketsread more
Bank of America says investors should still look to stocks for value rather than bonds.Investingread more
Online travel company Booking Holdings has dropped out of Facebook's libra, joining a growing list of firms who have exited the embattled cryptocurrency project.Technologyread more
"But I expect we'll have a deal," Mnuchin tells CNBC.Politicsread more
Kohl's stores are getting a bit of a refresh, and are being infused with new brands, ahead of this holiday season.Retailread more
Apple will release the iPhone SE2 early next year for $399, analyst Ming-Chi Kuo says.Tech Driversread more
State polls show that Trump's standing has weakened in some states hurt by the trade war.2020 Electionsread more
Sanders, who is recovering from a heart attack, reveals the new tax plan a day before the third Democratic debate.2020 Electionsread more
Investors are set to scrutinize results from Goldman Sachs and J.P. Morgan Chase as banks report third-quarter results starting Tuesday.Financeread more
Morgan Stanley slashed its price target on Netflix to $400 per share from $450 per share, but kept its overweight rating on the stock.Pro Analysisread more
There are at least 10,000 Islamic State prisoners in several camps across northeastern Syria, according to Kurdish and U.S. officials.Politicsread more
Cheaper biotech drugs are headed to the U.S., threatening big pharma companies like Johnson & Johnson. However, JPMorgan analyst Mike Weinstein thinks J&J can weather the storm.
The drugs are called biosimilar, which means they are not generic copies but instead are similar. The medications are manufactured using living cells and because it is so complicated, copycat versions can't be identical.
The first biosimilar drug was approved in the U.S. in March. However, legal battles have prevented it from hitting the market yet.
J&J's $5 billion arthritis drug Remicade could see competition within the next few years, Weinstein said Wednesday in an interview with CNBC's "Power Lunch." While it could happen before Remicade comes off patent, he thinks it will likely occur after the patent expires in late 2018.
He's convinced the company is prepared for when that happens.
"They're developing a pipeline, both internally and externally, that can help them manage through some of those challenges … as we go out to '18, '19, '20," Weinstein said.
Johnson & Johnson said Wednesday it plans to file for approval of 10 new medicines by 2019. Each drug has the potential to bring in more than $1 billion in revenue.
Weinstein noted that J&J's pharma business is 43 percent of its sales and 55 percent of its profit.
"The big driver of the company's performance historically and the stock is the pharmaceutical business," he said. "Over the last few years it's done exceptionally well."
Weinstein believes the business can grow in the 6 to 8 percent range over the next three to four years.
He also doesn't think the company needs to make a big acquisition to get that growth.
"If you look at their track record over the last 10 years, last 20 years, they've actually done a fantastic job of business development in pharmaceuticals," Weinstein said, noting it found opportunities in licensing compounds and buying smaller companies.
"They haven't needed to do a large deal in order to get the growth in the pharma that they're getting."
He thinks J&J can continue along the same course.
—CNBC's Meg Tirrell contributed to this report.